Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Average (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Equity Average data on record, last reported at $385.7 million in Q4 2025.

  • For Q4 2025, Equity Average rose 65.64% year-over-year to $385.7 million; the TTM value through Dec 2025 reached $385.7 million, up 65.64%, while the annual FY2025 figure was $299.3 million, 41.51% up from the prior year.
  • Equity Average reached $385.7 million in Q4 2025 per APLS's latest filing, up from $278.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $398.3 million in Q2 2022 and bottomed at -$99.4 million in Q3 2021.
  • Average Equity Average over 5 years is $225.8 million, with a median of $244.7 million recorded in 2022.
  • Peak YoY movement for Equity Average: crashed 158.84% in 2021, then soared 986.8% in 2022.
  • A 5-year view of Equity Average shows it stood at $70.7 million in 2021, then skyrocketed by 237.7% to $238.6 million in 2022, then fell by 10.58% to $213.4 million in 2023, then grew by 9.11% to $232.8 million in 2024, then surged by 65.64% to $385.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $385.7 million in Q4 2025, $278.7 million in Q3 2025, and $160.3 million in Q2 2025.